Purdue University

September ended and October began with an explosion of new venture capital available for biotech companies, raising expectations for VC fundraising by drug developers through the rest of 2024, especia

Lexeo Therapeutics Inc. became the 20th biopharma to launch an initial public offering in the US on 2 November when it sold 9.09 million shares at $11 each to gross $100m in its late-night public mar

Olema Pharmaceuticals, Inc. is not hurting for money after raising $139m in venture capital so far in 2020, but the company went public in the US on 18 November anyway to speed up clinical developmen

There are just two chimeric antigen receptor T-cell (CAR-T) therapies approved in the US, but dozens of companies already are clamoring to bring the next generation of CAR-T products to the market tha